| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300878 | 维康药业 | 27.93 | 6.68% | 7.22万 | | 2666T | | 002644 | 佛慈制药 | 9.21 | 4.66% | 25.93万 | | 2.38亿 | | 000423 | 东阿阿胶 | 51.39 | 1.50% | - 16.66万 | | 8.63亿 | | 600129 | 太极集团 | 17.66 | 0.68% | 17.40万 | | 3.12亿 | | 603896 | 寿仙谷 | 20.54 | 0.29% | 2.72万 | | 5605.12万 | | 301331 | 恩威医药 | 28.51 | 0.11% | 1.57万 | | 4552.78万 | | 600436 | 片仔瘦 | 160.40 | 0.00% | 3.58万 | | 5.80亿 | | 300147 | ST香雪 | 9.44 | 0.00% | 9.98万 | | 9473.45万 ...

经济观察网2026年1月30日，ST香雪（300147）发布2025年度业绩预告，预计2025年净利润亏损6.35亿 元至9.34亿元。扣除非经常性损益后的净利润亏损6.12亿元至8.99亿元。 ...

证券代码：300147 证券简称：ST 香雪 公告编号：2026-001 广州市香雪制药股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、业绩预计情况 二、与会计师事务所沟通情况 本次业绩预告相关的财务数据为公司财务部门初步测算结果，未经会计师事 务所审计。公司对业绩预告有关事项已与年报审计会计师事务所进行了预沟通， 公司与会计师事务所在本报告期的业绩预告方面不存在分歧。 三、业绩变动原因说明 2025 年，因市场竞争加剧和流动性危机，公司中成药销售不及预期，导致 收入减少和毛利率下降，加之财务费用高、资产负担重及减值准备，同时受预重 整影响，公司净利润仍处于亏损状态。影响公司 2025 年度经营业绩的主要因素 如下： 1、公司存续的短期及长期借款金额较大，财务费用约 25,000 万元。 2、固定资产折旧、摊销影响约 20,000 万元。 3、根据《企业会计准则第 8 号——资产减值》的规定，对合并报表范围内 存在减值迹象的资产进行了减值测试，预计需对存货、在建工程、固定资产、开 发支出等计提资产减值合计约 13,00 ...

Group 1 - The Chinese medicine sector saw a rise of 0.54% on January 20, with *ST Changyao leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Notable gainers in the Chinese medicine sector included *ST Changyao with a closing price of 0.53, up 20.45%, and ST Xiangxue with a closing price of 9.72, up 7.05% [1] Group 2 - The Chinese medicine sector experienced a net outflow of 23.25 million yuan from major funds, while retail investors saw a net inflow of 20.95 million yuan [2] - The top stocks by net inflow from retail investors included *ST Changyao and ST Xiangxue, with retail inflows of 2.20 million yuan and 4.16 million yuan respectively [3] - Major funds showed a significant net outflow in stocks like Zhongsheng Pharmaceutical and Yiling Pharmaceutical, with net outflows of 10.68 million yuan and 5.57 million yuan respectively [3]

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the five-day moving average, with a change of -0.03% [1] - The total trading volume of A-shares is 18505.22 billion yuan, with 228 A-shares breaking through the five-day moving average [1] Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Dapeng Industrial (证券代: 920091) with a deviation of 8.06% and a price increase of 10.14% [1] - Hongxing Development (证券代: 600367) with a deviation of 7.42% and a price increase of 10.01% [1] - Prologis Pharmaceutical (证券代: 000739) with a deviation of 7.37% and a price increase of 10.03% [1] Additional Notable Stocks - Other notable stocks with significant price movements include: - Lek Electric (证券代: 603355) with a deviation of 7.20% and a price increase of 9.99% [1] - Tianyi Medical (证券代: 301097) with a deviation of 6.87% and a price increase of 11.59% [1] - Meihu Co., Ltd. (证券代: 603319) with a deviation of 6.30% and a price increase of 7.73% [1] Stocks with Smaller Deviations - Stocks that have just crossed the five-day moving average with smaller deviations include: - Cangge Mining (证券代: 300300) with a deviation of 3.83% and a price increase of 5.01% [1] - ST Xiangxue (证券代: 300147) with a deviation of 3.57% and a price increase of 4.79% [1] - Shandong Molong (证券代: 002490) with a deviation of 3.43% and a price increase of 5.62% [1]

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

Group 1 - The core issue involves Xiangxue Pharmaceutical facing administrative penalties totaling 20.65 million yuan due to related party fund occupation and five years of financial fraud [1][2][3] - The company was found to have falsely reported profits in its 2019 annual report, inflating profits by 53.83 million yuan, which accounted for 45.98% of the total disclosed profit for that year [3] - The company failed to disclose losses from the demolition of five villas in December 2019, leading to significant omissions in its financial statements from 2016 to 2020 [3] Group 2 - Two categories of investors are eligible for compensation: those who bought shares between May 20, 2020, and April 29, 2024, and sold or still hold them at a loss after April 30, 2024, and those who bought shares between March 25, 2017, and September 30, 2024, and sold or still hold them at a loss after October 1, 2024 [4] - The legal actions are being supported by the recent regulatory penalties, which will serve as strong evidence in the upcoming investor compensation lawsuits [4]

Core Viewpoint - ST Xiangxue's subsidiary, Xiangxue Life Science, has received clinical trial approval for its new drug XLS-103 injection from the National Medical Products Administration, marking a significant milestone in its TCR T-cell therapy development [1] Group 1 - Xiangxue Life Science has obtained two clinical trial approval notices for XLS-103 injection, with notification numbers 2025LP03514 and 2025LP03515 [1] - The approval of XLS-103 injection is the sixth and seventh clinical trial notices related to TCR-T products developed by Xiangxue Life Science [1]

Core Viewpoint - ST Xiangxue announced that its subsidiary, Xiangxue Life Sciences, received clinical trial approval for the new drug XLS-103 injection, aimed at treating advanced non-small cell lung cancer and advanced pancreatic cancer with specific genetic mutations [1] Group 1 - The new drug is intended for patients with the HLA-A*11:01 genotype and KRAS G12V mutation [1] - This marks the sixth and seventh clinical trial notifications for TCR-T products obtained by Xiangxue Life Sciences based on its existing TCR-T cell therapy technology and R&D platform [1] Group 2 - The R&D of new drugs is characterized by long cycles, significant investment, high risks, and high added value [1] - The process involves many unpredictable factors, including technical and process challenges, leading to uncertainties in clinical trial progress and results [1]

证券代码：300147 证券简称：ST 香雪 公告编号：2025-057 广州市香雪制药股份有限公司 关于 XLS-103 注射液获得药物临床试验批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）子公司香雪生命科学技 术（广东）有限公司（以下简称"香雪生命科学"）收到国家药品监督管理局签 发的两份《药物临床试验批准通知书》（通知书编号分别为：2025LP03514、 2025LP03515），香雪生命科学的 XLS-103 注射液新药临床注册申请获得临床试验 许可。现将相关情况公告如下： 一、获得临床试验许可药品的基本情况 1、《药物临床试验批准通知书》（通知书编号：2025LP03514） 申请人名称：香雪生命科学技术（广东）有限公司 药品名称：XLS-103 注射液 获批适应症：用于治疗基因型为 HLA-A*11:01，肿瘤新生抗原 KRAS G12V 突变阳性的晚期非小细胞肺癌。 2、《药物临床试验批准通知书》（通知书编号：2025LP03515） 申请人名称：香雪生命科学技术（广东）有限公司 药品 ...